Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 7/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15889841 | 0.92 | TDP1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL19123153 | 0.92 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL9773831 | 0.92 | TDP1 (0.67) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL28425597 | 0.92 | TDP1 (0.62) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL25963707 | 0.90 | TDP1 (0.65) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL19243536 | 0.88 | TDP1 (0.54) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL15610483 | 0.87 | TDP1 (0.68) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL31040402 | 0.85 | CA14 (0.60) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL270450 | 0.85 | TDP1 (0.51) | TDP1MEN1GAAKMT2AMAOA | |
| SCHEMBL1206172 | 0.84 | TDP1 (0.60) | TDP1MEN1GAAKMT2AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247493-B2 | Long acting formulation of biopharmaceutical | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-08-21 | — | — | US | disclosed |
| US-8247493-B2 | Long acting formulation of biopharmaceutical | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2012-08-21 | — | — | US | disclosed |
| US-20110111477-A9 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20110111477-A9 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20100261245-A1 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSCO (KR) | 2010-10-14 | — | — | US | disclosed |
| US-20100261245-A1 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | POSCO (KR) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261245-A1 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | VEGFA, CD44, HACD3 | TDP1 1341/4885MEN1 3626/4885GAA 336/4885 |
| US-20110111477-A9 | LONG ACTING FORMULATION OF BIOPHARMACEUTICAL | VEGFA, CD44, HACD3 | TDP1 1341/4885MEN1 3626/4885GAA 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.